Variantyx snags $20m Series C

Variantyx, a provider of a genome sequencing-based testing program that diagnoses genetic disorders, has secured $20 million in Series C funding.

Variantyx, a provider of a genome sequencing-based testing program that diagnoses genetic disorders, has secured $20 million in Series C funding. GHS Fund led the round with participation from other investors that included IBM Ventures, Pitango Venture Capital, New Era Capital Partners and 20/20 HealthCare Partners.

Source: Press Release